12:00 AM
May 20, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MPDL3280A: Phase I data

Data from 140 patients with locally advanced or metastatic solid tumors whose disease had progressed despite prior therapy in an open-label, dose-escalation, international Phase I trial showed that IV MPDL3280A once every 3 weeks led to an ORR of 21%. Responders included patients with non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), colorectal cancer and gastric cancer. Roche's Genentech Inc. unit said that 26 of the 29 responders are continuing to...

Read the full 343 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >